Agreed, pitching!
AGEN has several checkpoint programs in Phase 1, a Prophage (-NEOish) GMB brain cancer vaccine in Phase 2, and infectious programs for shingles and malaria that are near market.
IMDZ has two cancer antigen-targeting in phase 2, one phase 1 and one pre-clinical. Also has a phase 2 infectious disease (RSV) candidate.
GNCA has no phase 3 assets and is still pre-clinical with personalized immuno-oncology product.
Above is sourced from the co's respective websites. I have no insight into these other vectors, efficacy/safety data, or the overall viability of any product relative to ADXS'. So while there are some personalized vaccine programs just a bit ahead of us, I am very much comfortable with where we stand relative to these examples, and am expecting great things from our HPV, PSA, Her2 franchises and am excited for the longer term future ADXS has laid out for -NEO and -HOT (as is AMGN, it appears!).
Best to you!